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ABSTRACT
A Role of Vitamin B2 in Reducing Amyloid-beta Toxicity in a Caenorhabditis elegans
Alzheimer’s Disease Model
by
Muhammad T. Ameen
Alzheimer’s disease (AD) is associated with amyloid-beta peptide deposition and loss of
mitochondrial function. Using a transgenic C. elegans AD worm model expressing amyloidbeta in body wall muscle, we determined that supplementation with either of the forms of
vitamin B2, flavin mononucleotide (FMN) or flavin adenine dinucleotide
(FAD) protected against amyloid-beta mediated paralysis. FMN and FAD were then assayed
to determine effects on ATP, oxygen consumption, and reactive oxygen species (ROS) with
these compounds not significantly improving any of these mitochondrial bioenergetic
functions. Knockdown of the daf-16/FOXO transcriptional regulator or the FAD synthase
enzyme completely abrogated the protective effects of FMN and FAD, while knockdown of
the mitochondrial unfolded protein response factors ubl-5 or atfs-1 also blocked the
protective effects. Therefore, vitamin B2 supplementation could lead to the activation of
conserved signaling pathways in humans to delay the onset and progression of
neurodegenerative diseases such as AD.
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CHAPTER 1
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disease associated with progressive
memory impairment, cognitive deficits, difficulty with language, and problem-solving skills
(Beitnere et al. 2014; Alzheimer’s Association 2017). This disease is irreversible and slowly
destroys memory and thinking skills and later prevents an individual to carry-out simple daily
activities (Rizzieri 2012). It is the most common cause of dementia among the older
population. AD is known to be the 6th leading cause of death in the United States and about
35 million people are affected worldwide (Prince et al. 2016). Despite years of funding for
research for into the pathological cause of AD and therapeutic development, it remains a
significant and unresolved physiological, financial, and social burden (Chen et al. 2015).
Some of the common risk factors that have been associated with AD include old age, family
history, lifestyle, gender, head injury, environmental toxins, and cardiovascular diseases such
as hypertension. So far, there is no cure for AD, however, emerging evidence has suggested
maintaining healthy aging and living style, such as healthy eating, engaging in social and
physical activities, and avoiding excess alcohol and smoking, could help to protect an
individual form developing AD. Also, much research has correlated brain health to heart
health, so chances of developing AD or any form of dementia increases with increased risk
for heart disease (Sandeep Kumar Singh et al. 2016). However, the number of deaths from
AD increased by 89 percent from 2000 to 2014 while deaths from heart disease decreased by
14 percent (Alzheimer’s Association 2017).
Despite numerous biomedical research discoveries suggesting therapeutic strategies
for AD, many of them have failed clinical trials. Current drugs used for treating patients with
AD include cholinesterase inhibitors and the NMDA receptor antagonist memantine that only
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delay symptoms of the disease without any modification of its direct cause (Misra and Medhi
2013). Therefore, the major problem for researchers and clinicians is identifying the etiology
of the disease and developing therapies or drugs that could prevent its onset or delay its
progression.

Molecular Pathology of Alzheimer’s Disease
The main pathological signatures of AD are the extracellular deposition of insoluble
amyloid-beta plaques and intracellular formation of neurofibrillary tangles in the
hippocampus region and cerebral cortex of the brain (Basurto-islas et al. 2010). These two
pathologies in the brain are thought to disrupt normal memory and cognitive functions of the
brain. Accumulation of these plaques and tangles later leads to common symptoms associated
with AD such as memory impairment, cognitive decline, personality changes and ultimately
death (Sandeep Kumar Singh et al. 2016). Since, 1906 when AD was first identified, and its
symptoms described by Alois Alzheimer, there have been concerted efforts by generations of
researchers and clinicians to identify direct pathological causes of the disease and develop
effective therapies and therapeutics (Goedert and Spillantini 2006; Santos et al. 2010). These
efforts have led to the development and testing of several hypotheses using different
experimental models. Also, results from these experiments have facilitated the discovery and
use of current drugs used for treating AD patients.
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Proposed Mechanisms for AD Development
Given the observations that multiple cellular mechanisms could be involved in the
pathology of AD, there have been several hypotheses proposed for its cause. The oldest of
these hypotheses is the cholinergic hypothesis, which postulates that reduced production of
the acetylcholine neurotransmitter in neurons of the forebrain leads to loss of neuronal
signaling and eventual loss of cognition and memory (Terry and Buccafusco 2003). However,
this theory has not been widely accepted because medications developed to treat
acetylcholine deficiency have not been effective. Other hypotheses proposed for AD include
tau protein hyperphosphorylation and the amyloid and mitochondrial cascade hypotheses
(Singh et al. 2016).
The current most widely established theory for AD is the “amyloid cascade
hypothesis”. This theory stipulates that AD develops due to the gradual accumulation of toxic
amyloid-beta peptide (AβP) in the medial temporal lobe of the brain due to proteolytic
cleavage of amyloid-beta-precursor-protein (AβPP) by β-secretase and γ-secretase. This
hypothesis therefore asserts that deposition of this peptide forms insoluble plaques in the
extracellular matrix of neurons thereby causing intracellular neurofibrillary tangles of tau
protein, neuronal cell loss, and vascular damage (Hardy and Higgins 1992). This toxic protein
accumulation has also shown to result in impaired brain cell energy metabolism, lower
oxygen uptake, increased toxic reactive oxygen species (ROS) production, and neuronal cell
death (Wang et al. 2015). Also, the familial form of AD, which arises due to mutations in the
AβPP (amyloid-beta precursor protein) gene has been linked to amyloid-beta deposition
(Owen et al. 1990). Unlike tau protein phosphorylation, which is also linked to other
neurodegenerative diseases known as tauopathies, the amyloid-beta peptide deposition has
only been linked to the onset of Alzheimer’s disease (Mudher and Lovestone 2002).
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Notwithstanding a plethora of research evidence relating amyloid-beta protein toxicity
to AD, there is lack of evidence as to what triggers the proteolytic production of amyloid-beta
from its precursor AβPP. A growing body of evidence now suggests that mitochondrial
dysfunction caused by excessive oxidative damage by ROS production triggers increased
production of the toxic amyloid-beta peptide, which later leads to a cascade of cellular
physiological disruptions and eventually cell death (Thannickal and Fanburg 2000). This later
assumption is known as the “mitochondrial cascade hypothesis”, which proposes the cause of
the most common type of AD, the sporadic or late onset AD (Swerdlow and Khan 2004).
Because of continuous shift in the understanding of the pathophysiological cause of
AD, several other mechanisms, such as hormonal imbalance, neuroinflammation, calcium
dysregulation, genetic defects, oxidative stress, autophagy and neuronal dysfunction, have
been proposed as upstream regulators for AD progression and that amyloid-beta plaque
formation and neurofibrillary tangles are downstream processes used by neuronal cells to
adapt to the continuously changing cellular environment (Anand et al. 2014).

Mitochondrial Biology of AD and Neurodegenerative Diseases
The significance of mitochondrial functions for cell survival has necessitated an
investigation into their role in the progression and onset of AD and other neurodegenerative
diseases. Maintaining normal cellular mitochondrial distribution and functions have been
reported to be challenging for aging cells, so dementia and other age-related neurological
diseases are a common culprit of mitochondrial dysfunction (Santos et al. 2010).
Mitochondria, the power-houses of cells, account for more than 90 percent of cellular
energetic needs (Chance et al. 1979). Since neurons have limited glycolytic capacity to
generate energy, they highly depend on energy derived from mitochondrial aerobic
12

respiration through oxidative phosphorylation (OXPHOS) for their extensive energydependent functions (Moreira et al. 2010). Although, the mitochondrial energy production
process generates toxic reactive oxygen species such as superoxide anions and downstream
hydrogen peroxide and peroxynitrite, normal cellular function requires superoxide as a
second messenger for cell signaling purposes (Shigenaga et al. 1994). However,
mitochondrial exposure to toxins and the aging process leads to the accumulation of
abnormally high ROS levels, which triggers abnormalities in mitochondrial function and
homeostasis, a hallmark of neurodegenerative diseases (Valko et al. 2007). Thus, impaired
mitochondrial function, homeostasis dysregulation, and abnormal mitochondrial dynamics
have been implicated in the onset and progression of AD and other neurodegenerative
diseases.

AD and Impaired Mitochondrial Function
One of the major functions of the mitochondria in cells is energy production though
the TCA (tricarboxylic acid) cycle and oxidative phosphorylation. Other than energy
production, mitochondria also trigger cell death or apoptosis and regulate Ca 2+ homeostasis
(Moreira et al. 2006; Wang et al. 2017). A considerable number of studies with laboratory
AD models, postmortem AD tissues, and AD patients have identified reduced mitochondrial
respiration and ATP production and increased ROS production. Using a C. elegans AD
model, Fong et al. 2016, reported that reduced ATP production and abnormalities in the
electron transport chain (ETC) protein complexes precede global metabolic failure and
pathology of AD. Also, Martire et al. 2016 have reported energetic decline in cell lines and
brain tissue of mice producing human amyloid-beta peptide (Aβ1–42). They also reported
that amyloid-beta peptide induced upregulation of PARP-1 (poly (ADP-ribose) polymerase),

13

an enzyme that catalyzes the ADP-ribosylation of proteins, leads to excessive degradation of
NAD+ (nicotinamide adenine dinucleotide), an important cofactor required for mitochondrial
energy production. Also, PARP-1 hyperactivation caused reduced mitochondrial cytochrome
c oxidase protein levels, oxygen consumption, and mitochondrial membrane potential.
Multiple studies have suggested that reduced brain glucose metabolism is a common
hallmark of AD patients and that energy impairment precedes clinical diagnosis of AD
symptoms. A study by Mosconi et al. (2011) reported glucose hypometabolism, increased
amyloid-beta deposition, and reduced activity of mitochondrial cytochrome c oxidase (COX),
in adult offspring of mothers with late-onset Alzheimer’s disease. Based on the
mitochondrial cascade hypothesis of AD proposed by Swerdlow and Khan (2004),
mitochondrial dysfunction due to oxidative damage is a potential target for AD therapeutics
development.

AD and Abnormal Mitochondrial Dynamics
Due to the significance of mitochondria in eukaryotic cells, abnormal modifications in
mitochondrial morphology and distribution can result in significant changes in cellular
functions and development of mitochondrial related diseases. Fan et al. (2010) have reported
that excessive mitochondrial oxidative damage causes increased mitochondrial fragmentation
or fission. A proper balance between mitochondrial fission (fragmentation) and fusion is
required for mitochondrial maintenance. Proteins located on mitochondrial outer and inner
membranes are responsible for regulating mitochondrial dynamics. Proteins required for
mitochondrial fission include the cytosolic GTPase Drp1 (dynamin-related-protein-1), Fis1
(fission 1), and mitochondrial fission factor (Mff). Drp1 is recruited to specific sites on the
mitochondrial outer membrane to initiate fission. Large GTPases such as mitofusins 1 (Mfn1)
14

and 2 (Mfn2) located on the mitochondrial outer membrane and optic atrophy 1 (OPA1)
located in the inner mitochondrial membrane regulate mitochondrial fusion (Yoon et al.
2003; Gandre-Babbe and van der Bliek 2008; Onoue et al. 2013).
Disruption of Drp1 activity is increased due to increased mitochondrial oxidative
damage causing frequent mitochondrial fission and abnormal cellular distribution of
mitochondrial populations and morphology. Barsoum et al. (2006) have reported increased
expression of Drp1 in cortical neuronal cultures treated with amyloid-beta peptide and nitric
oxide. They also reported reduced ATP production, mitochondrial ultrastructural damage,
and increased autophagy and generation of free radicals as possible consequences of the Drp1
induced excessive mitochondrial fission. Cho et al. (2009) have reported increased
mitochondrial fission in the brains of AD patients due to increased formation of SNO-Drp1
intermediates (S-nitrosylation of Drp1). Cho et al. also reported that amyloid-beta peptide
induced nitric oxide generation leading to increased synaptic loss and neuronal damage,
which are hallmarks of AD and neurodegenerative diseases. Interestingly, using a transgenic
mouse model of FAD (familial AD), Trushina et al. (2012) reported that alterations in
mitochondrial dynamics and morphology precedes neurological phenotypes and amyloid-beta
deposition. They also reported that altered mitochondrial energy metabolism and increased
mitochondrial stress accompany the altered mitochondrial dynamics. Therefore, regulation of
mitochondrial dynamics through the fission and fusion processes could also be a potential
therapeutic strategy for AD.

15

AD and Dysregulation of Mitochondrial Proteostasis
Targeting mitochondrial proteostasis regulation is an emerging trend in the prospect
for therapeutics for AD. Mitochondria possess mechanisms that regulate the expression of
proteins from mtDNA, the import of proteins from the cytoplasm and the transport of ions
across the inner mitochondrial membrane. These mitochondrial protein quality control
processes are often referred to as mitochondrial proteostasis. Inhibition of these processes by
amyloid-beta has been reported to result in inhibition of mitochondrial protein import,
OXPHOS impairment, and increased numbers of misfolded mitochondrial proteins (Devi et
al. 2006; Sorrentino et al. 2017). Also, evidence for the presence of amyloid-beta, functional
γ-secretase, and AβPP in mitochondria is an indication that mitochondria could either be a
production or storage site for amyloid-beta peptide. Amyloid-beta peptide inside the
mitochondrion has been shown to compromise cytochrome c oxidase (COX) activity and
increase mitochondrial ROS production. Also, the peptide induces cytochrome c dependent
caspase 3 activation, and decreased ATP production (Anandatheerthavarada et al. 2003;
Atamna and Frey 2004; Rhein et al. 2009). Thus, the loss of mitochondrial proteostasis could
also be involved in AD.

Mitochondrial Unfolded Protein Response Pathway
One important mechanism that is conserved in living cells from single celled
organisms to higher animals is the activation of conserved stress response pathways when
exposed to stressors such as toxins, starvation, misfolded proteins, or inhibition of normal
cellular function. However, the activation of some of these mechanisms has been reported to
decline with aging. Vital cell organelles such as endoplasmic reticulum and mitochondria
have evolved mechanisms that act as defense systems during cellular stress to protect the cell
16

from damage. Specifically, mitochondria have evolved a mechanism to regulate their folded
protein content (and proteostasis) during mitochondrial stress conditions such as during times
of limited mitochondrial protein import and accumulation of misfolded and unassembled
mitochondrial proteins (Jovaisaite et al. 2014). The most common defense mechanism
involved in this task is called the mitochondrial unfolded protein response (UPR mt). It
evolved to protect mitochondria from overwhelmed chaperones and to boost the activities of
proteasomal enzymes and mitochondrial proteases that degrade misfolded proteins. The
normal mitochondrial chaperone systems found in the matrix space (mtHSP70 and
HSP60/HSP10) and intermembrane compartments (protein quality control (PQC) proteases)
are overwhelmed during disease conditions associated with misfolded proteins. As a result,
the mitochondria sense the increased unfolded protein burden and induce the UPRmt to
improve protein quality control mechanisms through activation of ATFs (activating
transcription factors). Several of these factors have been identified in humans such ATF4 and
ATF5. However, this mechanism has been best studied in C. elegans models and is known to
require a master transcriptional regulator in this species called ATFS-1 (Activating
transcription factor associated with stress). ATFS-1 functions in conjunction with UBL-5
(ubiquitin-like protein-5) and DEV-1 (a homeodomain-containing transcription factor)
(Jovaisaite et al. 2014; Pickles et al. 2018).
Under normal conditions, ATFS-1, which has both a nuclear localization sequence
(NLS) and a mitochondrial targeting sequence, is imported into the mitochondria and
degraded by the LonP protease (Melber and Haynes 2018; Pickles et al. 2018). However,
during misfolded protein stress in mitochondria, ATFS-1 is translocated into the nucleus
together with DEV-1 to upregulate the transcription of a network of genes such as
chaperones, proteases and proteins required for mitochondrial import, metabolism and
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biogenesis. In this way mitochondria become protected and can once again resume optimal
function.
Activation of the mitochondrial unfolded protein response pathway has been reported
to decrease with aging suggesting this inability may participate in the onset and development
of many age-related diseases associated with misfolded proteins. For instance, Ruan et al.
2017, reported that defective cytosolic heat shock protein, Hsp70s, in yeast cells leads to an
increased entry of misfolded proteins into mitochondria. They also reported that blocking
mitochondrial protein import caused a decrease in proteasomal degradation with an increase
in mitochondrial stress. More so, in a study conducted by Sorrentino et al. 2017 to study the
role of mitochondrial proteostasis in worms, mice, and cell lines containing high levels of
amyloid-beta peptide (Aβ1-42), there was reduced mitochondrial respiration and an
upregulation of mitochondrial stress response pathways, mainly the mitochondrial unfolded
protein response pathway and mitophagy. Activation of these mitochondrial stress response
pathways was shown to improve health and lifespan of the C. elegans AD model studied and
also reduce amyloid-beta peptide deposition. Therefore, results from these and other studies
are indicators of the role of mitochondria in the onset and progression of AD and many other
neurodegenerative diseases caused by misfolded proteins.

Alzheimer’s Disease Drug Discovery Research
Alzheimer’s disease drug discovery research over the last three decades has only
yielded two types of drugs currently approved by the FDA for the treatment and management
of AD patients. These two types, acetylcholinesterase inhibitors and NMDA (N-methyl-Daspartate) receptor antagonists, only ameliorate the disease symptoms but have little to no
effect on the pathological process (Anand et al. 2014). Attempts by researchers to develop
18

effective therapies and therapeutics for AD have led to findings revealing more information
about the level of cellular complexities involved in the pathological progression of the
disease. Promising studies have found several natural compounds and genetic approaches to
modifying some of the currently known pathological causes of AD. Some of the strategies
used in Alzheimer’s disease drug discovery research include modulation of
neurotransmission, tau pathology inhibition, amyloid-beta based therapies, modulation of
intracellular signaling cascades, oxidative stress reduction, mitochondrial based therapies,
regulation of cellular calcium homeostasis, neuroinflammation based therapies, and other
emerging therapeutic strategies (Citron 2010; Grill and Cummings 2010; Anand et al. 2014).
Due to the complexities involved in AD pathological processes and the need for
studying therapeutic effects of multiple compounds, researchers have developed several
laboratory models based on amyloid-beta and tau production for high-throughput drug
screening of potential pharmacological and natural drug candidates for AD. Some of the most
commonly used laboratory models for studying AD pathology and therapeutics development
include transgenic mice, worms, flies, and mammalian cell lines expressing amyloid-beta
peptide (β1-42), mutant APP, or mutant tau protein (Sandeep Kumar Singh et al. 2016).

Amyloid-beta Based Strategies
Based on the understanding of the role of amyloid-beta peptide in AD pathology,
researchers have developed strategies to reduce amyloid-beta peptide production, modify its
cellular transport, prevent oligomerization, promote cellular clearance, or delay proteotoxicty.
One of the top strategies is an immunization-based approach (Anand et al. 2014). However,
amyloid-beta peptide likely plays some minor role in normal cellular physiological functions
such as in neurite outgrowth, synaptogenesis, cell adhesion, calcium metabolism, axonal
19

protein trafficking, and others. Amyloid-beta peptide is produced through the β-secretase and
-secretase (not α-secretase) cleavage of AβPP and the intracellular and extracellular
oligomerization of the peptide leads to the formation of Aβ fibrils and plaques. So, inhibiting
β-secretase or -secretase activity has been a potential strategy to prevent the production of
toxic Aβ-peptide species (Zheng and Koo 2006). But this strategy has largely failed in
clinical trials.
Treatments targeting amyloid-beta cellular transport are also being developed. The
apolipoprotein E (ApoE) and RAGE (Receptor for advanced glycation end products)
receptor-mediated transport of Aβ-peptide into and out of the brain are targets for AD drug
development (Anand et al. 2014). The ability of amyloid-beta peptide to oligomerize and
aggregate to form amyloid fibrils in the hippocampus and frontal brain region has been
shown to be a key factor in promoting its neurotoxicity. Drugs and plant extracts such as
tramiprosate (homotaurine), scyllo-inositol, the hormone melatonin, caffeine, NAD+
precursors, Gingko biloba, and others have been shown to possess anti-oligomerization
properties by interacting with the monomeric Aβ species and preventing their interaction to
form fibrils (Wu et al. 2006; Olcese et al. 2009; Dostal et al. 2010; Sorrentino et al. 2017). In
addition, genetic manipulations and immunotherapies are also being developed to delay Aβ
proteotoxicty and enhance Aβ clearance (Singh et al. 2016).

Mitochondrial Targeted Strategies
Mitochondrial dysfunction has also been shown to be involved in AD pathology
through the generation of excessive ROS leading to cellular oxidative damage and neuronal
cell death (Anand et al. 2014). Therapeutics targeted to mitochondria attempt to reduce
mitochondrial ROS production and improve activity and availability of enzymes and proteins
20

involved in mitochondrial energy production pathways such as the citric acid cycle, ETC, and
OXPHOS. Also, nutritional therapy for regulating mitochondrial dynamics and homeostasis
have been developed. Dietary supplementation of CoQ, a coenzyme required for electron
shuttling in the mitochondrial ETC, or MitoQ, a mitochondrial targeted derivative, have been
shown to possess neuroprotective effects by suppressing ROS production and improving
mitochondrial function (Wadsworth et al. 2008). Methylene blue has also been shown to have
neuroprotective effects to improve mitochondrial function by serving as an alternative
electron carrier of the ETC (Wen et al. 2011) to decrease ROS production. Other drugs
targeting mitochondrial ROS production and ETC have been proposed such as N-acetyl-Lcarnitine and R--lipoic acid, vitamins C and E, and Szeto-Schiller peptide-31 (SS-31)
(Anand et al. 2014).
Mitochondrial based therapies have also been developed to modify mitochondrial
dynamics (fission and fusion) and improve mitochondrial proteostasis. However, several of
these drugs have failed clinical trials and have been shown to affect normal cellular functions
and trigger inflammatory reactions in patients (Anand et al. 2014). Therefore, there is a need
to develop mitochondrial targeted treatments that solely target damaged mitochondria and
have minimal negative side effects on healthy mitochondria.
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Transcriptional Regulator DAF-16/FOXO
DAF-16 (Abnormal Dauer formation 16) is the C. elegans homolog of mammalian
FOXO transcription factors, which are induced in different cellular stress conditions. The
ability to activate DAF-16 declines with aging. FOXO transcription factors are involved in
cell cycle arrest, tumor suppression, protection against oxidative stress, and promotion of
longevity. They also upregulate genes involved in the innate immune response, DNA repair,
insulin sensitivity, and activation of gluconeogenesis. Four FOXO genes are present in
humans (FOXO1, FOXO3, FOXO4, and FOXO6), while only one is present in C. elegans
and Drosophila melanogaster, but multiple proteins are synthesized from the one gene in
these organisms. One of the key roles of FOXO proteins is to recruit chromatin modifying
enzymes to DNA to regulate target gene expression (Tia et al. 2018).
DAF-16/FOXO transcriptional activity is regulated by different proteins in response
to extracellular signals. The activity of the DAF-16/FOXO transcription factor can be
regulated through phosphorylation by Akt/ PKB, JNK (c-Jun N-terminal kinase), MST1
(mammalian ste20- like kinase 1), ERKs (extracellular signals regulated kinases), p38 MAPK
(mitogen-activated protein kinase), and AMPK (AAK-2 in C. elegans). Phosphorylation by
Akt in the cytoplasm prevents nuclear localization in response to insulin signaling, while
phosphorylation by the other kinases stimulates translocation form the cytoplasm to the
nucleus to modulate gene expression (Brunet et al. 2004). Some of the genes induced by
FOXO proteins include SOD2 and catalase (for ROS detoxification), PTEN (tumor
suppressor), P21CIP1 and P27KIP1 (cell cycle arrest), and PEPCK and G6Pase (during
starvation). Also, DAF-16/FOXO transcriptional activity is modulated by acetylation (by
HATs (Histone acetyltransferases)) , methylation (by PRMT1 and PRMT2 (protein arginine
N-methyltransferases 1 and 2)), and ubiquitin-dependent proteolysis (by SKP2 (S-phase
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kinase-associated protein 2)) (Yamagata et al. 2008; Tia et al. 2018). All four human FOXO
proteins are expressed in the brain.
FOXO transcriptional regulators have been shown to be activated through
pharmacological agents and genetic manipulations in C. elegans AD models. For instance,
Chondrogianni et al. (2014) reported that DAF-16 is required for enhanced proteasomal
degradation and reduced Aβ proteotoxicity in a C. elegans AD model overexpressing the β5
proteasome subunit. Several other studies have also reported DAF-16 to be required for the
protective effect of added compounds against amyloid-beta toxicity. Studies by Zhi et al.
(2017) and Wang et al. (2016) are examples of cases where compounds such as Dianxianning
(DXN) (a traditional Chinese formula) and royal jelly alleviate Aβ toxicity and improve AD
symptoms through DAF-16 activation. Thus, FOXO protein activation could be a target for
improving health and lifespan of AD patients.

A Caenorhabditis elegans AD Model
As the cost of maintaining a research laboratory is on the rise, biotechnology
companies and biomedical researchers have sought to develop quick and inexpensive
laboratory models with little maintenance cost, efficient handling, short reproduction time,
high level of gene and pathway conservation with vertebrates, and high amenability to
genetic manipulation. The worm C. elegans has now been extensively used as a laboratory
model to study developmental biology, embryology, disease mechanisms, and high
throughput drug screening for neurodegenerative disease (Teschendorf and Link 2009).
C. elegans is a free-living, transparent, and non-parasitic nematode with a short life
cycle of 3 days from egg to adult at 25°C (Brenner 1974). The mean lifespan of a worm
population is between two to three weeks and thus allows for a timely study of its biology
23

and therapeutic effects of drugs candidates for neurodegenerative diseases. In 1998 the
genome sequence of C. elegans was published. It shows 38 percent gene conservation with
humans (C. elegans Sequencing Consortium 1998). Although, C. elegans do not naturally
produce amyloid-beta peptide or show other AD-like memory phenotypes, orthologs of genes
mutated in familial AD such as APP, tau, and presenilin are present. Also, since C. elegans
neuronal connectivity has been established, worms have been very useful in studying the
pathology and drug interventions for AD (Alexander et al. 2014). One of the most prominent
genetic manipulations of C. elegans is RNAi interference (RNAi)-based gene knockdown.
This method has allowed for unbiased insights into C. elegans physiology (Teschendorf and
Link 2009).
C. elegans AD models have been developed based on amyloid-beta peptide and tau
pathology, the major correlates for AD progression. The most popular C. elegans AD model
expresses amyloid-beta peptide (β1-42) in the muscle leading to the formation of amyloidimmunoreactive inclusions and fibrils and paralysis (Lublin and Link 2014). Also, a
tauopathy worm model expressing either wild-type or mutated human tau protein has been
developed. Marked phenotypic consequences of Aβ or tau expression has allowed for easy
tracking and direct observation of Aβ and tau proteotoxicity (Singh et al. 2016).
One of the major limitations of using C. elegans as a neurodegeneration model is the
lack of evidence that the observed pathology in the worm is relevant for human disease. Also,
amyloid-beta needs to be overexpressed in worms at higher levels to induce the same level of
toxicity observed in human brains or mammalian cell lines (Teschendorf and Link 2009).
Other experimental limitations of C. elegans disease models is the absence of the immune
system and the relative ineffectiveness of the RNAi technique in neurons, although this
second limitation can be overcome by genetic manipulation (Firnhaber and Hammarlund
2013). Also, some challenges of using C. elegans for drug screening is the inability of some
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compounds to penetrate the thick worm cuticle and false positive or negative results from
compounds that are metabolized by the bacteria that the worms are co-cultured with to
consume as a food source. However, these can mostly be overcome by using worm strains
engineered to have a more permeable cuticle (Partridge et al. 2008) or increasing drug dosage
or time of supplementation (Alexander et al. 2014).

Neurological Importance of B Vitamins
B vitamins are a class of water-soluble vitamins that play key roles in brain energy
metabolism. B vitamins serve as precursors for coenzymes involved in cellular metabolism,
most prominently in mitochondrial energy production. For instance, vitamin B2 (riboflavin) is
a precursor for FAD (flavin adenine dinucleotide) and FMN (flavin mononucleotide), while
vitamin B3 (niacin) is a precursor for NAD (nicotinamide adenine dinucleotide), all three of
which serve as electron carriers for mitochondrial energy production. Other types of B
vitamins such as B1 (thiamine), B5 (pantothenic acid), B6 (pyridoxine), B7 (biotin), B9 (folate),
and B12 (cobalamin) play key roles as cofactors and molecules mediating multiple brain
functions (Kennedy and Haskell 2011).
B vitamins cannot be synthesized in the human body, except for niacin (vitamin B3)
which can be synthesized to a limited extent from the essential amino acid tryptophan, and
must be regularly obtained from the diet (Sechi et al. 2016). Natural sources of vitamin B1
include brown rice, fruits, vegetables, and seafoods, while vitamin B2 is naturally present in
dark green vegetables, meat (liver), dairy products, and whole grains. However,
epidemiological studies have shown that B vitamin deficiency is on the rise in both developed
and developing countries, especially among the older population, vegetarians, patients with
heart failure, and postoperative bariatric surgery. Vitamin B1 and B2 deficiency is more
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prevalent among the elderly (Sechi et al. 2016). Due to interactions between B vitamin
functions, specifically the role of active forms of riboflavin (FMN and FAD) as an enzyme
cofactor involved in the synthesis of other classes of B vitamins, B 2 deficiency has been
shown to limit folate, pyridoxine, and cobalamin availability (McCormick 1989; Sechi et al.
2016).

Vitamin B Deficiency and Neurodegenerative Diseases
Due to lack of robust tissue storage of B vitamins, cells depend on a regular supply of
B vitamins for vital functions and to prevent disease-symptoms associated with their
deficiency. The physiological importance of B vitamins, such as for energy production,
amino acid metabolism, synthesis of proteins and neurotransmitters, and synthesis of
cholesterol and nucleotides bases, have made their cellular deficiencies a leading cause of
many neurological and cardiovascular diseases. Specifically, active forms of vitamin B2 and
B6 have roles as antioxidants in cellular processes (Powers 2003).
Several lines of evidence have suggested vitamin B supplementation as a strategy to
improve brain function and reduce incidence of neurological diseases. For instance, vitamin
B1 (thiamine) deficiency has been associated with neurological problems such as cognitive
deficits and encephalopathy. Thiamine-dependent enzymes perform critical roles in brain
glucose metabolism. As a result, reduced levels of these enzymes have been reported in
brains of AD patients. In contrast, excess levels of thiamine have been shown to diminish
AD-like pathologies (Gibson et al. 2016).
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Vitamin B2 Synthesis and Metabolism
Vitamin B2 (also known as riboflavin) is not synthesized by humans and must be
obtained from the diet. Vitamin B2 is present abundantly in a wide variety of animal and plant
foods such as in legumes, meat ,and dairy products, etc. (Udhayabanu et al. 2017). The
chemical structure of riboflavin consists of an isoalloxazine ring and a ribityl side chain.
Riboflavin obtained from the diet is enzymatically converted to FMN by riboflavin kinase by
the addition of a phosphate group to its ribityl side chain. FMN may then be converted to
FAD by the FAD synthase enzyme by the addition of an adenine monophosphate group
(AMP). FAD can be converted back to riboflavin by FAD pyrophosphatase (This process is
called the Rf-FAD cycle.). Riboflavin has a half-life of approximately one hour and is
mainly stored in the liver, spleen, kidney and cardiac muscle in the form of FAD. Thus, its
deficiency could impair essential functions of these vital organs (Saedisomeolia and Ashoori
2018). FMN and FAD are the main active forms of vitamin B2 and perform active roles as
coenzymes of enzymes and proteins called flavoproteins, mostly involved in mitochondrial
metabolic processes.
Mutations in riboflavin transporters and riboflavin-dependent enzymes can limit
absorption, transport, or conversion of riboflavin to its different active forms leading to
disease. Specifically, mutation in FAD synthase (FLAD1) causes FAD deficiency in patients
diagnosed with multiple acyl-CoA dehydrogenase deficiency (MADD) (Auranen et al.
2017a). Also, mutations in riboflavin plasma membrane and mitochondrial transporters have
been shown to contribute to the development of MADD, with riboflavin supplementation
decreasing disease symptoms and improving mitochondrial flavoprotein activities. Other
symptoms of riboflavin deficiency have been reported in rat studies to include demyelination
in the cerebrum and cerebellum and delay and impairment in brain development and
maturation (Udhayabanu et al. 2017).
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Riboflavin also plays a key role as an antioxidant in the glutathione redox cycle. FAD
is involved in the activation of the glutathione reductase (GR) enzyme through its reduction
by reduced nicotinamide adenine dinucleotide phosphate (NADPH). This crucial step is
required for the continuous activity of the glutathione redox cycle (Saedisomeolia and
Ashoori 2018). As a result, cellular riboflavin status is commonly obtained through
measurement of GR activity. Riboflavin deficiency could therefore potentially play a role in
the development and treatment of neurodegenerative diseases where oxidative stress is
increased.
Due to a dearth of effective and readily available disease modifying therapeutics for
AD treatment and due to the failure of multiple clinical trials of already proposed drugs, there
is a need to develop new strategies that could address the complex multifactorial causes of
AD onset and progression. Because of this necessity, this study was conceived to study the
role of vitamin B2 in delaying amyloid-beta induced proteotoxicity using both mitochondrial
and amyloid-beta cascade hypotheses as rationale. Therefore, our initial hypothesis was that
vitamin B2 supplementation would improve mitochondrial bioenergetic function, which
would in turn improve amyloid-beta clearance to delay amyloid-beta induced proteotoxicty in
a C. elegans amyloid beta-expressing AD model.
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CHAPTER 2
MATERIALS AND METHODS

Caenorhabditis elegans Strain Maintenance
C. elegans AD model strain CL4176 (smg-1(cc546)+ [myo-3p::A-Beta (1-42)::let851 3'UTR) + rol-6(su1006)]) expressing Aβ1-42 peptide specifically in body wall muscle at
25°C, but not 15°C, through the use of a temperature-inducible expression system and wildtype N2 strain were obtained from the Caenorhabditis Genetics Center (CGC, University of
Minnesota). The CL4176 worm strain was maintained at the permissive temperature of 15°C
on Nematode Growth Media (NGM) agar 10 cm plates and fed with the OP50-1 (or
HT115(DE3) for RNAi experiments) Escherichia coli bacterial strain, while wild type N2
worms were cultured similarly as a control.

Chemicals
Nicotinic acid (RPI), nicotinamide adenine dinucleotide (NAD +) (Alfa Aesar),
nicotinamide adenine dinucleotide phosphate (NADP+) disodium salt (Alfa Aesar), flavin
adenine dinucleotide (FAD) disodium salt (TCI), riboflavin-5’-phosphate (FMN) (Alfa
Aesar), Carbenicillin disodium salt (RPI corporation), IPTG (Fisher scientific), (adenosine-5triphosphate (ATP) disodium salt hydrate (MP Biomedicals) and Nystatin (RPI corporation).

Drugs Preparation and Concentrations
The water-soluble vitamins B2 and B3 were dissolved in either double deionized water
or M9 buffer. The active forms of vitamin B2 (riboflavin), FMN and FAD, were used at
varying concentrations until a protective concentration was obtained. FMN was used at final
concentrations of 0.07 mM, 0.37 mM, 0.74 mM and 1.48 mM. FAD was used at final
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concentrations of 0.2 µM, 0.37 µM, 0.74 µM, 2.2 µM, 3.7 µM, and 37 µM. Vitamin B3
(niacin) was

used in both the precursor (nicotinic acid) and active forms, NAD and NADP.

Nicotinic acid was used at final concentrations of 0.07 mM, 0.37 mM, 0.74 mM, and 1.11
mM. NAD was used at final concentrations of 1.48 µM, 1.85 µM, 2.22 µM, 3.70 µM, 7.40
µM, and 14.80 µM. Lastly, NADP was used at final concentrations of 0.37 µM, 1.48 µM,
2.96 µM, and 7.40 µM.

Amyloid-beta Peptide Mediated Paralysis Assays
To test for a protective effects against amyloid-beta peptide induced paralysis, worms
were assayed to determine any delay in paralysis after administration of different
concentrations of vitamin B2 or B3 using methods described by Dostal and Link 2010.
Briefly, age synchronized worm populations were obtained by picking 30 gravid adult worms
onto several freshly prepared drug-free (no vitamins added) NGM agar plates using a
dissecting stereo microscope with a worm picker. Worms were allowed to lay eggs for 2-3
hours at 15°C and gravid adult worms were picked off. Eggs were then allowed to hatch and
grow on NGM (0.01 mg/ml streptomycin (an antibiotic) and (0.01 mg/ml nystatin or 0.01
mg/ml fluconazole (antifungals)) plates at 15°C for 7 days. On the 7th day, 10-12 gravid adult
worms were picked onto freshly prepared NGM plates containing appropriate drug (B
vitamin) concentrations or controls. After 3-4 hours of egg laying on the drug-containing or
control NGM plates, gravid adult worms were picked off while eggs were allowed to hatch
and grow at 15°C for 48 hours. After 48 hours of growth at 15°C, all plates were upshifted to
a 25°C incubator for 30 hours. After 30 hours of incubation and growth at 25°C, worms were
assayed for paralysis at 2 hours intervals for 20-30 hours or until all worms on the plates had
paralyzed. Paralyzed worms were detected by prodding worms with a worm picker (platinum
wire) under a dissecting microscope. Paralyzed worms cannot translocate across the plate,
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will cease to move after 2-3 proddings, or cannot form bacterial halos around their moving
heads without whole body movement. At least 65 worms were used in triplicate for each
treatment group.

Obtaining Worm Samples for ATP, Oxygen Consumption, and Reactive Oxygen Species
(ROS) Assays
Confluent gravid adult worms growing on 3-5 drug-free NGM plates at 15°C for 7 days were
bleach synchronized to obtain eggs of approximately equal age. Equal numbers of hatched eggs were
grown on 12-well plates containing liquid S-media, 0.01 mg/ml fluconazole, and the appropriate drug
concentration together with 1 x 1010 CFU OP50-1 E. coli per ml. Worms were grown at 15°C with
shaking for 48 hours. Plates were then upshifted to 25°C to induce Aβ-peptide expression with
shaking for 36 hours. After 36 hours of incubation at 25°C, the 800-1000 worms in each well were
washed thoroughly with ice-cold 0.1 M NaCl solution in a 15 ml centrifuge tube 4 times at 2500 rpm
for 2 minutes to remove bacteria. 1 ml of worm pellets were then transferred to 1.5 ml centrifuge
tubes and spun down at 5,000 rpm for 5 minutes. 500 µl of sample suspension was then divided into 3
taking 350 µl worms for the oxygen consumption assay, 50 µl of worms for the ROS assay, and 100
µl of worms for the ATP and BCA protein quantification assays. 100 µl of worm samples for ATP
and BCA assays were snap frozen in liquid nitrogen and stored at -80°C for later use.

ATP assays
Worms treated with the protective FMN (0.74 mM) and FAD (0.74 µM)
concentrations were assayed for changes in ATP level using the CellTiter-Glo (Promega,
Madison, WI) firefly luciferase system as described by Edwards et al. 2013. As described
above, 100 L of worm samples were pelleted, snap frozen to disrupt membranes and release
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ATP, and stored at -80°C. For analysis, the samples were thawed on ice and divided into
equal halves. 50 µl of the worm sample was used for BCA protein quantification assay while
50 µl was used for the ATP assay. 50 µl of each sample was added into a well of a 96-well
plate with 50 µl of CellTiter-Glo reagent. The plate was then shaken for 2 minutes at room
temperature and incubated for 10 minutes at room temperature in a Biotek Synergy 2
microplate reader after which the luminescence of the samples was measured. ATP
concentrations in the samples were calculated using a standard curve of known ATP
concentrations.

Oxygen Consumption Assays
Worms were assayed for basal oxygen consumption using methods described by
Edwards et al. 2013 using a Clark oxygen electrode (MT200A chamber, Strathkelvin
Instruments). 350 µl of worm sample containing approximately 700 worms was added to the
electrode chamber and respiration was monitored for 5 minutes for each sample. Basal worm
oxygen consumption was normalized to protein concentration.

ROS Assays
Worms were assayed for ROS levels using the method described by Delic et al.
(2017). Briefly, 50 µl of live worms containing approximately 100 worms were added into
each well of a 96-well plate with 50 µl of the dye 5’-dichlorodihydrofluorescein diacetates
(DCFH2-DA). The plate was shaken in the dark for 2 minutes and then incubated in the dark
for 30 minutes to allow for the dye penetration into the worms. The plate was then read for
ROS-induced DCF fluorescence using a Biotek Synergy 2 microplate reader for 4 hours at 10
minutes intervals. Worm ROS levels were calculated using the slope of the fluorescence
curve and normalized to protein concentration.
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BCA Protein Quantification Assay for ATP, Oxygen Consumption, and Reactive Oxygen
Species (ROS) Assays
Measurements from ATP, oxygen consumption, and ROS assays were standardized to
protein content. Protein quantification was performed using the method described by
Edwards et al. (2013) with slight modification. Flash frozen worm samples were thawed on
ice and vacuum dried to remove excess washing buffer using a speed vacuum SC110A
(Savant) for 1 hr. Worm pellets were then dissolved in 20 µl of 1 M NaOH solution heated at
70°C for 25 minutes. Worm samples were cooled on ice and vortexed. 200 µl of deionized
water was added to each sample to give a concentration of 0.1 M NaOH. Samples were
centrifuged at 14, 000 rpm for 5 minutes. 25 µl of each sample was used for protein
quantification using a BCA assay kit (Pierce) according to the manufacturer’s instruction.

RNAi Feeding Experiments
E. coli daf-16, ubl-5, and flad-1 RNAi clones were obtained from the Ahringer C.
elegans RNAi library (Source BioScience Life Sciences). The atfs-1 E. coli RNAi clone
from the Vidal RNAi library was purchased from Dharmacon. Using methods described by
Edwards et al. (2015) and the Ahringer group who synthesized the E. coli RNAi library
(Kamath et al. 2000), clones were grown in LB liquid media with 50 M ampicillin at 37°C
with shaking at 220 rpm for 18 hours. Bacteria cultures were pelleted and resuspended in
sterile double deionized water at a concentration of 100 mg/ml and stored at 4°C until further
use. NGM plates for RNAi experiments contained appropriate vehicle controls or
concentrations of FMN or FAD at 0.74 mM and 0.74 µM respectively. Also, the plates
contained final concentrations of 25 g/ml carbenicillin and where appropriate 1 mM IPTG
(to induce dsRNA production). Synchronized worm populations feeding on the appropriate E.
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coli RNAi clone (daf-16, ubl-5, flad-1, or atfs-1) were then grown on these plates and
assayed for Aβ-mediated paralysis.

Statistical Analysis
Statistical analysis for the paralysis curves was performed with Kaplan-Meier survival
analysis and the Log-Rank test using Sigma plot version 11.0 software. Each replicate
experiment of the paralysis assays was done in triplicates. Statistical analysis for bioenergetic
assays was performed using One-way ANOVA repeated measures with GraphPad Prism
version 7.04. Bioenergetic assays experiments were repeated four times in triplicates. All data
were analyzed to check for outliers.
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CHAPTER 3
RESULTS

Protective Effects of B Vitamins on Amyloid-beta Mediated Paralysis
This study investigated the protective effects of B vitamins, specifically vitamins B 2
and B3, on the toxicity of amyloid-beta peptide using a C. elegans AD model. In this model,
temperature upshift induces amyloid-beta expression in body wall muscle leading to a
paralysis in some worms beginning at 30 hours following upshift with greater than 90% of
worms paralyzing by 40 hours after upshift. Paralysis assays using different concentrations
of active forms and precursors of these two B vitamins were performed.

Figure 1 Effect of FMN Treatment on Amyloid-beta Mediated Paralysis
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The active forms of B2 (FMN and FAD) protected the worms against amyloid-beta
toxicity depending upon the concentration added. FMN addition significantly delayed
paralysis at the three highest concentrations tested with increased mean worm survival
ranging from 13 % to 22 % (Figure 1, Table 1) when compared with the control group, while
the lowest concentration slightly increased the rate of paralysis. Only one of the two FAD
concentrations tested (0.74 µM) significantly protected against amyloid-beta toxicity and this
concentration delayed mean paralysis time by 13 % (Figure 2, Table 1). The 3.7 M
concentration had no significant effect on the mean time to paralysis.

Figure 2 Effect of FAD Treatment on Amyloid-beta Mediated Paralysis
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Nicotinic acid (a vitamin B3 precursor) supplementation moderately protected the
worms against amyloid-beta toxicity at one of the three concentrations tested (0.74 mM)
(Figure 3) and at this concentration increased mean time to paralysis by 10 % (Table 1)
compared to the control group. Two other lower NA concentrations used decreased mean
time to paralysis by 13 % and 14 %.

Figure 3 Effect of Nicotinic Acid (NA) Treatment on Amyloid-beta Mediated Paralysis.

Active forms of vitamin B3 (NAD and NADP) were also assayed to determine if they
could provide protection against amyloid-beta-mediated toxicity. NAD addition delayed
mean time to paralysis by 15 % at a concentration of 1.85 µM and by 3 % at a concentration
of 7.40 µM (Figure 4), while two concentrations added did not lead to protection with one
concentration even facilitating paralysis. NADP addition failed to protect against amyloidbeta toxicity at either of the two limited concentrations tested with one concentration
decreasing time to paralysis (Figure 5, Table 1).
37

Figure 4 Effect of NAD Treatment on Amyloid-beta Mediated Paralysis

Figure 5 Effect of NADP Treatment on Amyloid-beta Mediated Paralysis.
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Table 1 The Effects of B Vitamins on Aβ-peptide Mediated Paralysis in a C. elegans AD
Model
Treatment

Concentration

% change in
mean paralysis
time

p-value

# of worms

Replicates

FMN
(flavin
mononucleotide)

0.07 mM
0.37 mM
0.74 mM
1.48 mM

-6
+13
+13
+22

<0.001
<0.001
<0.001
<0.001

342
148
325
156

2
3
3
2

FAD
(flavin adenine
dinucleotide)

0.74 µM
3.7 µM

+13
+2

<0.001
0.055

385
191

5
2

NA
(nicotinic acid)

0.07 mM
0.37 mM
0.74 mM

-14
-13
+10

<0.001
<0.001
<0.001

271
163
1060

2
2
8

NAD
(nicotinamide
adenine
dinucleotide)

1.85 µM
2.22 µM
3.7 µM
7.40 µM

+15
0
-9
+3

<0.001
0.915
<0.001
0.003

232
202
205
595

1
3
2
6

1.48 µM
2.96 µM

0
-4

0.854
<0.001

446
403

4
2

NADP
(nicotinamide
adenine
dinucleotide
phosphate)
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Effects of Vitamin B2 on Mitochondrial Bioenergetic Function and Cellular Energy
Metabolism
Since vitamin B2 is an essential cofactor for several mitochondrial enzymatic
reactions, the concentrations of FMN (0.74 mM) and FAD (0.74 µM) that protected against
amyloid-beta toxicity by 13% were assayed for changes in measures of mitochondrial
bioenergetic function and cellular energy metabolism including ATP level, oxygen
consumption, and reactive oxygen species (ROS) production. Figure 6 shows ATP levels of
untreated, FMN treated, or FAD treated Aβ-expressing worms (strain CL4176) and untreated
wild-type N2 worms. FMN or FAD treatment did not show a significant effect on ATP
levels.

Figure 6 Effect of FMN and FAD Treatment on ATP Level
The data indicate the mean and standard error of the mean (SEM) of four
independent triplicate trials. The p values compared to untreated amyloid-beta
expressing worms are 0.40, 0.59, and 0.64 for FMN treated, FAD treated, and
untreated wild type N2 worms respectively.
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The basal oxygen consumption rate of FMN or FAD treated, and untreated CL4176
worms was also measured as well as that of wild type N2 worms (Figure 7). FMN or FAD
treatment or A expression did not significantly alter the rate of oxygen consumption.

Figure 7 Effect of FMN and FAD Treatment on the Basal Oxygen Consumption Rate
The data indicate the mean of four independent triplicate trials with error bars representing
the SEM. The p values compared to untreated amyloid-beta expressing worms are 0.63,
0.72, and 0.99 for FMN treated, FAD treated, and untreated wild type N2 worms
respectively.

The effect of FMN or FAD supplementation on reactive oxygen species (ROS)
production in the amyloid-beta expressing CL4176 worms was also determined and
compared to untreated wild-type N2 worms (Figure 8). Although there were trends for
increased ROS levels in CL4176 worms and decreased ROS levels following FMN or FAD
treatment these values were not significantly different than the control. For consistency
among assays, ROS levels were measured from the same cohort of worms used for the ATP
and oxygen consumption measurements.
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Figure 8 Effect of FMN and FAD Treatment on Reactive Oxygen Species (ROS) Production
The means and SEMs shown are from four repeated triplicate trials. The p values compared
to untreated amyloid-beta expressing worms are 0.32, 0.33, and 0.30 for FMN treated, FAD
treated, and untreated wild type N2 worms respectively.

Effects of DAF-16/FOXO or FAD Synthase Knockdown on Vitamin B2 Protection
To identify molecular mechanisms through which vitamin B2 functions to protect
from amyloid-beta peptide toxicity, the stress response transcriptional regulator DAF16/FOXO was knocked down by RNA interference (RNAi) and the worms were assayed for
FMN or FAD-mediated protection from amyloid-beta mediated paralysis. All RNAi
knockdown experiments were repeated three times in triplicate with each point on the graphs
representing the mean of all worms for all groups. For RNAi knockdown experiments worms
were fed the HT115(DE3) strain of E. coli used for making the whole genome knockdown
library instead of the standard OP50-1 strain. This change caused an increase in the mean
paralysis time of control worms from approximately 35 hours to 45 hours. Concentrations of
FMN or FAD that increased the mean paralysis time by 13% when using OP50-1 bacteria
were used.
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Figure 9 shows results of FMN treatment of worms feeding on daf-16 RNAi
knockdown E. coli and assayed for amyloid-beta peptide mediated paralysis. Untreated
control groups were also fed daf-16 RNAi knockdown bacteria or empty vector (ev) bacteria
as controls. Knockdown of daf-16 did not significantly alter the rate of paralysis in untreated
worms. FMN treatment of empty vector fed worms increased mean paralysis time by 14 %
compared with the empty vector control fed worms, while FMN treatment of daf-16
knockdown worms decreased mean paralysis time by 7 % (Table 2) when compared to the
empty vector control fed worms (Table 2). Therefore DAF-16 is required for the protective
effects of FMN treatment on amyloid-beta toxicity.

Figure 9 DAF-16 is Required for the Protective Effect of FMN on Amyloid-beta
Mediated Paralysis
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Figure 10 shows the effects of FAD supplementation on amyloid-beta mediated
paralysis in the presence of daf-16 knockdown. FAD treated empty vector fed worms showed
a 21 % increase in mean paralysis time, while FAD treatment of daf-16 knockdown worms
did not significantly alter their rate of paralysis (Table 2). Therefore, DAF-16 is required for
FAD mediated protection from amyloid-beta toxicity.

Figure 10 DAF-16 is Required for the Protective Effects of FAD on Amyloid-beta
Mediated Paralysis
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The C. elegans flad-1 gene is homologous to the human FAD synthase gene whose
protein product converts FMN to FAD. In attempt to determine the most protective active
form of vitamin B2, worms were subjected to flad-1 RNAi feeding and treated with either
FMN or FAD. As shown in Figure 11, knockdown of flad-1 in untreated worms decreased
mean paralysis time by 12 % indicating that decreased FAD levels likely sensitize the worms
to amyloid-beta toxicity. FMN treatment of empty vector fed worms increased paralysis time
by 14 %, while FMN treatment of flad-1 RNAi knockdown did not alter the mean time to
paralysis compared to untreated flad-1 knockdown worms (Table 2). Therefore, FLAD-1 is
required for FMN-mediated protection from amyloid-beta toxicity.

Figure 11 FLAD-1 is Required for FMN Mediated Protection Against Amyloidbeta Toxicity
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Similarly, flad-1 RNAi knockdown experiments were performed with FAD
supplementation as shown in Figure 12. FAD supplementation of empty vector fed worms
increased mean paralysis time by 21 %. FAD supplemented, flad-1 knockdown worms had a
mean paralysis time roughly equal to untreated flad-1 knockdown worms. Surprisingly,
FLAD-1 appears to be equally important for the protective effects of FAD supplementation
as it is for FMN supplementation.

Figure 12 FLAD-1 is Required for FAD Mediated Protection Against Amyloid-beta
Toxicity
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Table 2 Vitamin B2 Requires DAF-16 and FAD Synthase for Protection Against Aβ-peptide
Toxicity in a C. elegans AD Model
RNAi
treatment

Treatment

empty
vector
(ev)

Control
0.74 mM FMN
0.74 µM FAD

daf-16

Control
0.74 mM FMN
0.74 µ FAD

flad-1

Control
0.74 mM FMN
0.74 µM FAD

% change
from control
mean paralysis
time

% change from
empty vector,
control mean
paralysis time

p-value

# of
worms

Replicates

<0.001
<0.001

384
336
291

3
3
3

-3

0.200
0.064
0.206

175
279
156

3
3
3

-12

<0.001
0.908
0.325

255
338
336

3
3
3

0
+14
+21

-4
+4

0
-1

Effect of Vitamin B2 Supplementation on Worms Where Mitochondrial Unfolded Protein
Response (UPRmt) Pathway Genes are Knocked Down
FMN or FAD supplementation was further tested for the ability to delay amyloid-beta
mediated paralysis in worms where mitochondrial unfolded protein response pathway genes
ubl-5 or atfs-1 were knocked down. Knockdown of ubl-5 or atfs-1 did not alter the rate of
paralysis in untreated worms. FMN was slightly more effective in these experiments than in
previous experiments increasing the time to paralysis by 27 % in empty vector fed worms.
Worms treated with FMN and ubl-5 RNAi bacteria feeding did not have a significantly
different mean time to paralysis than untreated ubl-5 RNAi worms or untreated, empty vector
control worms (Table 3 and Figure 13). Therefore, UBL-5 is required for the protective
effects of FMN on amyloid-beta mediated toxicity.
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Figure 13 The Mitochondrial Unfolded Protein Response Factor UBL-5 is Required for
FMN Mediated Protection Against Amyloid-beta Toxicity

Similar experiments were performed with FAD supplementation as shown in Figure
14 and Table 3. In these experiments FAD supplementation to empty vector fed worms was
slightly less protective than in previous experiments increasing mean time to paralysis by
only 7%. However, ubl-5 knockdown of FAD treated worms completely prevented the FADmediated increase in mean time to paralysis. Therefore, UBL-5 is required for FADmediated protection from amyloid-beta toxicity.
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Figure 14 The Mitochondrial Unfolded Protein Response Factor UBL-5 is Required for FAD
Mediated Protection Against Amyloid-beta Toxicity

To verify the effects of ubl-5 knockdown, a transcriptional regulator of the UPRmt,
atfs-1, was knocked down. FMN treatment increased mean time to paralysis by 27% in the
empty vector treated worms. FMN treatment of atfs-1 knockdown worms led to a 11 %
increase in time to paralysis (Figure 15 and Table 3). This indicates either a partial
requirement of atfs-1 for FMN-mediated protection or possibly incomplete knockdown of
atfs-1 by the RNAi clone used. Either way the data support a role for the UPR mt in the
protective effects of FMN on amyloid-beta mediated toxicity.
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Figure 15 The Mitochondrial Unfolded Protein Response Factor ATFS-1 is Partially
Required for FMN Mediated Protection Against Amyloid-beta Toxicity

Similar experiments were also performed with atfs-1 knockdown and FAD
supplementation. Once again FAD supplementation was slightly less effective in these
experiments only increasing the mean time to paralysis by 7% in the empty vector fed worms.
However, atfs-1 knockdown prevented the increase in mean time to paralysis in the FAD
treated worms as shown in Figure 16 and Table 3. Therefore, UPR mt is required for the FAD
mediated protection from amyloid-beta toxicity.
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Figure 16 The Mitochondrial Unfolded Protein Response Factor ATFS-1 is Partially
Required for FAD Mediated Protection Against Amyloid-beta Toxicity

Table 3 The Mitochondrial Unfolded Protein Response Factors UBL-5 and ATFS-1 are
Required for FMN and FAD Mediated Protection Against Aβ-peptide Toxicity in a C.
elegans AD Model.
RNAi

Treatment

% change from
control
mean paralysis
time

empty
vector
(ev)

Control
0.74 mM FMN
0.74 µM FAD

ubl-5

Control
0.74 mM FMN
0.74 µM FAD

-1
-3

Control
0.74 mM FMN
0.74 µM FAD

+11
+3

atfs-1

% change from
empty vector,
control mean
paralysis time

p-value

# of
worms

Replicates

<0.001
<0.001

410
244
203

3
3
3

+1

0.979
0.701
0.032

532
340
350

3
3
3

0

0.734
<0.001
0.336

396
392
309

3
3
3

0
+27
+7
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CHAPTER 4
DISCUSSION

B vitamin deficiency has been linked to the development and onset of several diseases
such as cancers, heart disease, and neurodegenerative diseases (Saedisomeolia and Ashoori
2018). This class of vitamins is water soluble and is most abundantly found in plant and
animal human food sources such as legumes, milk, organ meats, sea foods, etc. B vitamins
are also essential nutrients that must be consumed as part of the human diet (although vitamin
B3, niacin, can be synthesized at a low level in the body from the amino acid tryptophan)
(Sechi et al. 2016). Due to evidence linking B vitamin deficiencies, specifically B2 deficiency,
to the development of AD and other neurological diseases (Udhayabanu et al. 2017), this
study was initiated to investigate a possible protective role of vitamin B2 supplementation on
amyloid-beta toxicity, a pathological hallmark of AD, in a C. elegans AD model.

A Protective Role of Vitamins B2 and B3 Against Amyloid-beta Mediated Paralysis
Data from our experiments suggest a protective function of the active forms of
vitamin B2 (FMN and FAD) against amyloid-beta toxicity. FMN or FAD supplementation
resulted in a delay in amyloid-beta mediated paralysis by 22 % and 13 % respectively at
optimal concentrations (Figure 1-2, Table 1). Although, there has been no study testing for a
protective role of FMN or FAD in any C. elegans neurodegenerative disease models, several
human clinical trials and molecular studies using high dose riboflavin supplementation have
reported improved symptoms and improvement in biomarkers of disease such as improved
cognitive function (Bell et al. 1992), improved muscular function (Anand et al. 2012; Foley
et al. 2014), or increased flavoenzyme activities such as glutathione reductase antioxidant
activity (riboflavin-dependent) (Hoey et al. 2009).
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Given the importance of the active forms of vitamin B3, NAD(H) and NADP(H), in
hundreds of cellular redox and biosynthetic reactions, including their role as cofactors for
metabolic and antioxidant enzymes, it was not unexpected that supplementation with an NAD
precursor, nicotinic acid (0.74 mM), at an optimal concentration delayed amyloid-beta
mediated paralysis (Figure 3, Table 1). This result is consistent with studies reported by
Sorrentino et al. (2017) using an alternative NAD precursor, nicotinamide riboside, which
was protective when supplemented to the GMC101 C. elegans strain (an alternative AD
worm model constitutively expressing amyloid-beta in body wall muscle). This is also
consistent with our finding that an optimal supplemented concentration of NAD (1.85 µM)
protected against amyloid-beta mediated paralysis (Figure 4, Table 1). However, NADP
supplementation failed to protect against amyloid-beta mediated paralysis even at a higher
concentration of 7.4 µM (Figure 5, Table 1). This could be due to either a low absorption rate
of NADP by the worms (due to the negative charge of the phosphate group) or due to us not
finding the optimal dose (Chen et al. 2015), as NADP(H) levels are roughly 10 fold lower
than NAD(H) levels in the cell. NADPH serves as a cofactor for the reduction of glutathione
reductase in the glutathione redox cycle. NADPH is 20-100 fold more abundant than its
oxidized form NADP and controls the rate limiting step of the glutathione cycle
(Saedisomeolia and Ashoori 2018). Thus, the failure of NADP (oxidized) supplementation to
protect against amyloid-beta toxicity could be due to its excessive accumulation and
alteration of the physiological NADP/NADPH ratio. NADPH is oxidized to NADP in
solution fairly rapidly, so NADPH supplementation to the worms would almost undoubtedly
lead to similar results as NADP supplementation.
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Vitamin B2 Supplementation and Mitochondrial Bioenergetic Function
Our data shows no significant difference in ATP levels, oxygen consumption, or
reactive oxygen species (ROS) production between FMN or FAD treated CL4176 worms and
untreated controls. There was also no significant difference in the mitochondrial bioenergetic
function between treated or untreated CL4176 AD worms and wild-type N2 worms. In the
AD worm model we used, amyloid-beta is only expressed in body wall muscle. Although
amyloid-beta is known to inhibit complex IV of the electron transport chain, this is likely not
measurable in this worm strain where over 80% of the cells do not express amyloid-beta.
Both FMN and FAD serve as important coenzymes for several essential mitochondrial
enzymes functioning in energy production or apoptosis. The simplest explanation for the lack
of effect of FMN or FAD on mitochondrial bioenergetics function is that FMN and FAD are
endogenously present at high enough levels that exogenous supplementation does not further
increase mitochondrial enzyme activities. Results from supplementation with these two
compounds (Figures 6-8) on mitochondrial bioenergetic function in this C. elegans model
should not be extrapolated to suggest that vitamin B2 does not play a protective role on
mitochondrial bioenergetics in other human diseases.
Studies conducted by Karakoyun et al. (2017) reported riboflavin supplementation to
reduce reactive oxygen species generation in acetic-acid induced colonic injured rats. Also,
Peluchetti et al. (1991) reported riboflavin supplementation to increase the maximal oxygen
consumption rate of a muscle biopsy in a small clinical trial of four patients with multiple
acyl-coenzyme A dehydrogenase deficiency (MADD). Riboflavin supplementation also
improved mitochondrial function or disease state in disease models resulting from a
deficiency in mitochondrial enzymes such as those required for the assembly of
mitochondrial complex I in a complex I-mutant C. elegans strain or in cells deficient in
complex IV activity (Grad and Lemire 2006). Another possible reason for no significant
54

effect of FMN or FAD supplementation on mitochondrial bioenergetic function might be due
to the low supplementation dose when compared to other studies where riboflavin was
supplemented at much higher doses. For example, high dose supplementation showed
significant delay in disease progression in clinical studies of Brown-Vialetto-Van Laere
syndrome (a disease associated with respiratory insufficiency in children) (Anand et al.
2012).

Vitamin B2 May Activate Transcriptional Regulators of Stress Response Pathways
We further investigated a role of the stress response transcriptional regulator DAF-16
in the protective effects of FMN and FAD to delay amyloid-beta toxicity. RNAi knockdown
of daf-16 significantly blocked the protective effect of FMN or FAD supplementation on
amyloid-beta mediated paralysis (Figure 9 & 10, Table 2). This data suggests that FMN and
FAD protect through activation of DAF-16. This discovery may provide a possible answer to
a question posed by many biomedical researchers and clinicians for the main molecular
mechanism through which riboflavin supplementation is protective. Since humans have 4
homologs of DAF-16 (FOXO1, FOXO3, FOXO4, and FOXO6), which can induce protective
gene expression programs such as stimulation of antioxidant genes and autophagy genes,
induction of one or more of these FOXO genes may be responsible for the protective effects
reported in published animal and clinical riboflavin supplementation studies, such as those
reported by Shukitt-Hale (2012) and Saedisomeolia and Ashoori (2018). Our results on the
dependency of DAF-16 for protection by FMN or FAD are different from the results of the
study reported by Sorrentino et al. (2017) where nicotinamide riboside (NR) supplementation
protected GMC101 AD worms. NR supplementation significantly delayed amyloid-beta
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mediated paralysis like we found for FMN or FAD supplementation. However, the protective
effects of NR did not rely upon DAF-16 activation.
Knockdown of flad-1 (an ortholog of human FLAD1) completely prevented the
protective effects of added FMN or FAD on amyloid-beta toxicity (Figure 11 & 12, Table 2).
This suggests a key role for FLAD-1 in maintaining a balanced FMN/FAD ratio for the
protective effects observed. In line with our findings of the significance of FLAD-1 function
during FMN or FAD supplementation, Auranen et al. (2017) reported that riboflavin
supplementation ameliorated disease symptoms in patients suffering from partial loss of
function of the FLAD1 enzyme resulting in multiple acyl-CoA dehydrogenase deficiency
(MADD). Given the fact that deficiency of normal endogenous FLAD1 activity levels lead to
abnormal flavin metabolism and cause disease and that flad-1 knockdown sensitizes worms
to amyloid-beta toxicity, our findings suggest an important role of increased levels of FAD in
activating DAF-16 and UPRmt to protect against amyloid-beta toxicity. In addition, since
flad-1 knockdown prevents the protective effects of FAD supplementation, added FAD may
get catabolized to riboflavin and then resynthesized to FMN and FAD to exert its protective
effects.

Vitamin B2 Activation of the Mitochondrial Unfolded Protein Response Pathways
In addition to activation of the DAF-16 stress response pathway by FMN or FAD
supplementation, the essential factors of the UPRmt ubl-5 (ubiquitin-like protein, UBL5) and
atfs-1 (Activating transcription factor associated with stress) were also required for the
protective effects. UBL-5 is required for normal mitochondrial morphology, assembly of
mitochondrial multi-protein complexes, and induction of the UPRmt (Benedetti et al. 2006).
In contrast to the results presented here where no effect was shown on CL4176 worms, ubl-5
56

or atfs-1 knockdown facilitated paralysis in untreated GMC101 amyloid-beta expressing
worms.
ATFS-1 shares sequence homology with several proteins in the ATF transcription
factor family in mammals. Mammalian ATF4 or ATF5 are activated during mitochondrial
dysfunction and translocate to the nucleus to activate networks of mitochondrial stress
response genes required for the UPRmt and mitochondrial proteostasis (Melber and Haynes
2018). Thus, results from ubl-5 and atfs-1 RNAi knockdown experiments suggest a role for
high levels of vitamin B2 in upregulating genes required for mitochondrial protein refolding
(Grad and Lemire 2006) and protein import. The UPRmt was shown to be activated in
GMC101 worms by the mitochondrial dysfunction caused by amyloid-beta peptide
deposition (Sorrentino et al. 2017), while it may not have been activated in the untreated
CL4176 strain of worms that we used, as we did not find that knockdown of UPRmt factors
hastened the rate of paralysis.

Conclusions
This study has established that supplementation with the appropriate concentrations of
the active forms of vitamin B2 (FMN or FAD) can protect against amyloid-beta peptide
toxicity through activation of the DAF-16/FOXO stress response pathway and the
mitochondrial unfolded protein response (UPRmt) pathway. Although, our initial hypothesis
was that vitamin B2 supplementation would improve mitochondrial bioenergetic function,
results from our findings have suggested otherwise. Thus, it can be concluded from this study
that vitamin B2 supplementation might serve a limited role in improving cellular metabolic
function such as improving mitochondrial bioenergetic function, but instead protect through
inducing the transcription of genes associated with cellular stress response pathways.
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Future Studies and Study Limitations
To further confirm the protective roles of FMN or FAD supplementation through the
activation of conserved stress response signaling pathways, the following future experiments
could be conducted in C. elegans:


Perform RNAi knockdown of the riboflavin kinase gene (R10H10.6) to confirm if
inhibition of endogenous FMN synthesis can prevent the protective effects of added
FMN or FAD.



Treat SOD-3::GFP expressing DAF-16 reporter worms with FMN or FAD to check
for the transcriptional activation of the SOD-3 promoter by the DAF-16/FOXO
transcription regulator.



Perform lifespan assays of FMN or FAD supplementation and check for genes
required for lifespan extension.



Treat HSP-6::GFP or HSP-60::GFP expressing UPRmt reporter worms with either
FMN or FAD to check for upregulation of GFP expression through mitochondrial
unfolded protein response activation.
The study has the following limitations. The C. elegans AD model used for
this study only expresses the amyloid-beta peptide, Aβ1-42, and not full-length APP
since C. elegans apparently lack the  and  secretases involved in the processing of
APP to toxic amyloid-beta peptide. Amyloid-beta is expressed in body wall muscle
instead of neurons as only a much delayed, mild phenotype was observed when the
peptide was expressed in neurons. Also, the peptide must be overexpressed in the
worms at a higher level to induce the same level of toxicity observed as when
expressing it in mammalian brains or cell lines. Therefore, similar experiments with
FMN or FAD treatment should be performed in mammalian models of amyloid-beta
toxicity to confirm the findings presented here.
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